Mesoblast Limited (ASX:MSB) updated on upcoming milestones for its lead product candidate remestemcel-L, along with the activity report for the 4th quarter ended 30 June 2020.
Phase 3 Trial of Remestemcel-L for COVID-19 ARDS is anticipated to complete its recruitment in September 2020 in the US.
The ODAC (Oncologic Drugs Advisory Committee) of the US FDA has scheduled a meeting on 13 August 2020 to review data supporting MSB’s Biologics License Application for approval of RYONCIL in the treatment of SR-aGVHD in children.
Mesoblast disclosed that the company has cash on hand of US$129.3 million at the end of the quarter. Moreover, MSB completed a capital raising of ~US$90 million from global institutional investors in May 2020.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.